Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies-Reference-Cited by-同舟云学术

Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies

Published:2014-10-06 Issue:1 Volume:17 Page:32-41
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Wang T.¹²,Wang F.³,Gou Z.⁴,Tang H.²,Li C.²,Shi L.¹,Zhai S.²

Affiliation:

1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences; Peking University Health Science Center; Beijing China

2. Department of Pharmacy; Peking University Third Hospital; Beijing China

3. Department of Pharmacy Practice, School of Pharmacy; University of Connecticut; Storrs CT USA

4. Department of Pharmacy; First Affiliated Hospital of Harbin Medical University; Harbin China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12386/fullpdf

Reference49 articles.

1. Pancreatic safety of incretin-based drugs - FDA and EMA assessment;Egan;N Engl J Med,2014

2. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012